Country
Switzerland
Roche has stopped dosing patients in a Phase 3 study of an investigational drug for Huntington’s disease, a rare genetic condition that causes nerve cells in the brain to break down.
Full text available to subscribers only. Click here for information on subscribing to MedNous.